More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma

被引:7
作者
Hogen, Rachel [1 ]
Lo, Mary [2 ]
DiNorcia, Joseph [3 ]
Ji, Lingyun [2 ]
Genyk, Yuri [1 ]
Sher, Linda [1 ]
Dhanireddy, Kiran [1 ]
机构
[1] Univ Southern Calif, Dept Surg, Div Hepatobiliary Pancreas & Abdominal Organ Tran, Los Angeles, CA USA
[2] Univ Southern Calif, Dept Preventat Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Dept Surg, Div Liver & Pancreas Transplant, Los Angeles, CA USA
关键词
BRIDGING LOCOREGIONAL THERAPY; UNITED NETWORK; SURVIVAL; LIST; RECURRENCE; MODEL;
D O I
10.1097/TP.0000000000002248
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Regional allocation of deceased donor livers has led to variable wait times for hepatocellular carcinoma (HCC) patients on the liver transplant list. The purpose of our study was to evaluate how regional differences in wait time affect outcomes for HCC patients. Methods. A retrospective, observational study was performed using the Organ Procurement and Transplantation Network database from February 27, 2002, to September 25, 2015. The cumulative incidences of transplant and waitlist death as well as intention-to-treat and posttransplant survival were evaluated for patients 18 years or older listed for deceased donor liver transplantation with stage II HCC exception points in each United Network for Organ Sharing region. A multivariable analysis of predictive factors for posttransplant survival was performed. Results. Cumulative incidence of transplant decreased and cumulative incidence of waitlist death increased as regional wait time increased. Intention-to-treat survival decreased with increased regional wait time with long wait time regions 1, 5, and 9 having significantly lower intention-to-treat survival compared with many of the shorter wait time regions (P < 0.05). Wait time did not predict posttransplant survival. Significant predictive factors of posttransplant survival included alpha-fetoprotein, size of the largest tumor, number of tumors, age of the recipient, laboratory model for end-stage liver disease, donor risk index, period of transplantation, and region (P < 0.05). Conclusions. Wait time inequality affects waitlist mortality and intention-to-treat survival but does not affect posttransplant survival. Posttransplant survival is predicted by tumor biology, graft quality, recipient age, underlying liver function, and region. Regional environments of HCC care seem to drive posttransplant survival.
引用
收藏
页码:747 / 754
页数:8
相关论文
共 20 条
[1]   Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium [J].
Agopian, Vatche G. ;
Harlander-Locke, Michael P. ;
Ruiz, Richard M. ;
Klintmalm, Goran B. ;
Senguttuvan, Srinath ;
Florman, Sander S. ;
Haydel, Brandy ;
Hoteit, Maarouf ;
Levine, Matthew H. ;
Lee, David D. ;
Taner, C. Burcin ;
Verna, Elizabeth C. ;
Halazun, Karim J. ;
Abdelmessih, Rita ;
Tevar, Amit D. ;
Humar, Abhinav ;
Aucejo, Federico ;
Chapman, William C. ;
Vachharajani, Neeta ;
Nguyen, Mindie H. ;
Melcher, Marc L. ;
Nydam, Trevor L. ;
Mobley, Constance ;
Ghobrial, R. Mark ;
Amundsen, Beth ;
Markmann, James F. ;
Langnas, Alan N. ;
Carney, Carol A. ;
Berumen, Jennifer ;
Hemming, Alan W. ;
Sudan, Debra L. ;
Hong, Johnny C. ;
Kim, Joohyun ;
Zimmerman, Michael A. ;
Rana, Abbas ;
Kueht, Michael L. ;
Jones, Christopher M. ;
Fishbein, Thomas M. ;
Busuttil, Ronald W. .
ANNALS OF SURGERY, 2017, 266 (03) :525-535
[2]   Development of organ-specific donor risk indices [J].
Akkina, Sanjeev K. ;
Asrani, Sumeet K. ;
Peng, Yi ;
Stock, Peter ;
Kim, W. Ray ;
Israni, Ajay K. .
LIVER TRANSPLANTATION, 2012, 18 (04) :395-404
[3]   Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma [J].
Charriere, Berenice ;
Maulat, Charlotte ;
Suc, Bertrand ;
Muscari, Fabrice .
WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (21) :881-890
[4]   Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma [J].
Croome, Kristopher P. ;
Lee, David D. ;
Harnois, Denise ;
Taner, C. Burcin .
PLOS ONE, 2017, 12 (01)
[5]  
Elwir Saleh, 2016, Gastroenterol Hepatol (N Y), V12, P166
[6]   Characteristics associated with liver graft failure: The concept of a donor risk index [J].
Feng, S ;
Goodrich, NP ;
Bragg-Gresham, JL ;
Dykstra, DM ;
Punch, JD ;
DebRoy, MA ;
Greenstein, SM ;
Merion, RM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (04) :783-790
[7]   Recurrence After Liver Transplantation for Hepatocellular Carcinoma A New MORAL to the Story [J].
Halazun, Karim J. ;
Najjar, Marc ;
Abdelmessih, Rita M. ;
Samstein, Benjamin ;
Griesemer, Adam D. ;
Guarrera, James V. ;
Kato, Tomoaki ;
Verna, Elizabeth C. ;
Emond, Jean C. ;
Brown, Robert S., Jr. .
ANNALS OF SURGERY, 2017, 265 (03) :557-564
[8]   Standing the Test of Time: Outcomes of a Decade of Prioritizing Patients With Hepatocellular Carcinoma, Results of the UNOS Natural Geographic Experiment [J].
Halazun, Karim J. ;
Patzer, Rachel E. ;
Rana, Abbas A. ;
Verna, Elizabeth C. ;
Griesemer, Adam D. ;
Parsons, Ronald F. ;
Samstein, Benjamin ;
Guarrera, James V. ;
Kato, Tomoaki ;
Brown, Robert S., Jr. ;
Emond, Jean C. .
HEPATOLOGY, 2014, 60 (06) :1957-1962
[9]   Delayed Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Score Improves Disparity in Access to Liver Transplant in the United States [J].
Heimbach, Julie K. ;
Hirose, Ryutaro ;
Stock, Peter G. ;
Schladt, David P. ;
Xiong, Hui ;
Liu, Jiannong ;
Olthoff, Kim M. ;
Harper, Ann ;
Snyder, Jon J. ;
Israni, Ajay K. ;
Kasiske, Bertram L. ;
Kim, W. Ray .
HEPATOLOGY, 2015, 61 (05) :1643-1650
[10]   Locoregional Therapy and Recurrence of Hepatocellular Carcinoma After Liver Transplant [J].
Kirnap, Mahir ;
Boyvat, Fatih ;
Akdur, Aydincan ;
Karakayali, Feza ;
Arslan, Gulnaz ;
Moray, Gokhan ;
Haberal, Mehmet .
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2014, 12 :166-169